Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Yair Lotan, MDUrothelial Carcinoma Diagnostics | January 15, 2025
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
View More
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | January 13, 2025
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Emily MenendezAdvanced Urothelial Carcinoma | January 10, 2025
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
Daniel M. Geynisman, MDMuscle Invasive Urothelial Carcinoma | January 10, 2025
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | January 9, 2025
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Yair Lotan, MDUrothelial Carcinoma Diagnostics | January 8, 2025
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Emily MenendezUpper Tract Urothelial Carcinoma | January 7, 2025
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | January 7, 2025
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Neal Shore, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | January 6, 2025
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Neal Shore, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | January 6, 2025
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | January 3, 2025
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Zachary BessetteRenal Cell Carcinoma | January 2, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 18, 2024
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 17, 2024
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | December 16, 2024
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Advertisement
Advertisement
Advertisement